Use case · Pharmaceuticals & Life Sciences
Regulatory dossier assembly in pharmaceuticals & life sciences
Automating regulatory dossier assembly where GxP validation means every system change needs documented evidence before it reaches production.
- Sector
- Pharmaceuticals & Life Sciences
- Systems involved
- 5
- Regulations in scope
- 5
What makes this hard
In pharmaceuticals & life sciences, GxP validation means every system change needs documented evidence before it reaches production. Applied to regulatory dossier assembly, that means the automation has to carry an audit trail and a clean escalation path before it carries any speed benefit at all.
Every engagement opens with a measurement: the cycle time, the cost per transaction, or the error rate we are being asked to move.
Built by engineers who ship production systems, not by a practice that subcontracts the build. You own the code, the models where they are open-weight, and the documentation to run it without us.
How we sequence it
- 01BaselineMeasure the current cycle time, touch count and error rate on regulatory dossier assembly. Without that number there is no way to prove the automation worked.
- 02Map the exceptionsDocument what actually happens when the process does not run cleanly. The exceptions, not the happy path, decide whether this automation survives contact with real operations.
- 03Integrate firstConnect to LIMS and QMS before building any intelligence on top. A model that cannot reach the system of record cannot finish the work.
- 04Ship narrowAutomate the highest-volume, lowest-variance slice and put it in front of real users, with anything uncertain escalated to a human.
- 05Measure and widenReport the straight-through rate against the baseline, then absorb the next tier of exceptions. Coverage rises over time rather than being promised on day one.
Context
- Workload
- regulatory dossier assembly
- Sector
- Pharmaceuticals & Life Sciences
- Sector constraint
- GxP validation means every system change needs documented evidence before it reaches production
- Systems of record
- LIMS · QMS · eTMF · SAP · pharmacovigilance databases
- Regulations in scope
- CDSCO · US FDA 21 CFR Part 11 · EU GMP Annex 11 · GxP validation · ICH guidelines
Capabilities that deliver this
- AI Agent Development for Pharmaceuticals & Life Sciences
- Agentic Workflow Automation for Pharmaceuticals & Life Sciences
- LLM Application Development for Pharmaceuticals & Life Sciences
- RAG & Knowledge Retrieval for Pharmaceuticals & Life Sciences
- Chatbot Development for Pharmaceuticals & Life Sciences
- Document Processing & IDP for Pharmaceuticals & Life Sciences
Questions
Can regulatory dossier assembly be automated reliably?
The high-volume, low-variance portion can, with anything uncertain escalated to a human. In pharmaceuticals & life sciences, GxP validation means every system change needs documented evidence before it reaches production, so the escalation path matters as much as the automation itself.
What does it integrate with?
Typically LIMS, QMS, eTMF, SAP, pharmacovigilance databases. We assess your specific estate during discovery rather than assuming a standard setup.
What about compliance?
CDSCO, US FDA 21 CFR Part 11, EU GMP Annex 11, GxP validation, ICH guidelines are in scope for this sector. Audit trail and human oversight are built in from the start, not added before go-live.
Can an AI system be GxP validated?
Yes, with a documented validation approach, IQ/OQ/PQ, defined intended use, change control and evidence of consistent performance. We build the validation pack alongside the system, not afterwards.
How do you handle 21 CFR Part 11?
Audit trails, electronic signatures, access control and record integrity designed in from the start, because retrofitting them is effectively a rebuild.
Other pharmaceuticals & life sciences workloads
Automating regulatory dossier assembly?
Bring us your current cycle time. We will tell you what is realistically removable.
Or email bd@dtrasglobal.com · call +91 74118 77878